Biodesix reports Q4 EPS (49c) vs. ($1.13) last year

Reports Q4 revenue $28.76M, consensus $26.25M. “Biodesix (BDSX) delivered exceptional results in the fourth quarter, with revenue of $28.8 million and 83% gross margin,” said Scott Hutton, CEO. “We exceeded the high end of our revenue guidance by delivering 41% growth, and for the first time ever, achieved Adjusted EBITDA positivity in the quarter demonstrating the strength of our operating leverage and gross margins, which have become a hallmark of Biodesix performance. In 2025, we accelerated the growth of our lung-focused commercial strategy, expanded our pipeline, announced new partnerships, grew our development services offering, and presented clinical data on our on-market and pipeline products.”